 Merck Co Inc NYSE: MRK is reportedly mulling buying cancer-focused biotech Seagen Inc NASDAQ: SGEN, Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagens market value of roughly 28. 